GRI Bio Announces Exercise of Warrants
1. GRI Bio exercises existing warrants for 762,236 shares at $1.00 each. 2. Gross proceeds estimated at $0.8 million for working capital. 3. New Series D-1 and D-2 warrants issued alongside common stock. 4. Company focuses on NKT cell modulators for autoimmune diseases. 5. Forward-looking statements highlight potential market challenges.